Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Ann Oncol. 2022 Oct 5;34(1):111–120. doi: 10.1016/j.annonc.2022.09.163

Table 1.

Clinicopathological covariables

Tumor type Variables used in modeling
mCRPC Line number, practice type (community versus academic), age at therapy start, race, ECOG performance score, albumin below normal limits, alkaline phosphatase above normal limits, hemoglobin below normal limits, neutrophil-to-lymphocyte ratio, log2 prostate specific antigen
mBC Line number, practice type (community versus academic), age at therapy start, race, ECOG performance score, hormone receptor status, Her2 status, sites of metastasis
aNSCLC Line number, practice type (community versus academic), age at therapy start, race, ECOG performance score, sex, smoking status, EGFR mutation status, KRAS mutation status, BRAF mutation status, sites of metastasis, histology
mCRC Line number, practice type (community versus academic), age at therapy start, race, ECOG performance score, sex, BRAF V600E mutation status, RAS mutation status, ERBB2 mutation status, sidedness at diagnosis

A panel of covariates was specific for each type of cancer. Variables were selected based on a combination of documented prognostic relevance in the tumor type and availability in the clinico-genomic database (CGDB). All variables were measured within the same 60-day pre-therapy window as TF except: hormone receptor and HER2 statuses in breast counted any pre-therapy positive result as positive for the patient, sites of metastasis counted all metastases detected pre-therapy, sidedness of CRC was indexed to initial diagnosis.

aNSCLC, advanced non-small-cell lung cancer; CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; mBC, metastatic breast cancer; mCRC, metastatic colorectal cancer; mCRPC, metastatic castration-resistant prostate cancer; TF, tumor fraction.